ArticleCase reports in oncology

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer.

Lorenz Frehner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.